TV 5010
Latest Information Update: 10 Mar 2011
Price :
$50 *
At a glance
- Originator Teva Pharmaceutical Industries
- Class Amino acids; Peptides
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Crohn's disease; Multiple sclerosis; Neurological disorders
Most Recent Events
- 31 Dec 2006 Discontinued - Phase-II for Crohn's disease in Israel (SC)
- 31 Dec 2006 Discontinued - Phase-II for Multiple sclerosis in Europe (SC)
- 15 Jun 2006 Phase-II clinical trials in Crohn's disease in Israel (SC)